Erik Sulman, MD, PhD, is a Professor and Vice-chair of Research in the Department of Radiation Oncology at the New York University Grossman School of Medicine and the Co-director of the Brain and Spine Tumor Center in the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health. In addition, Dr. Sulman is Co-director of the NYU Grossman School of Medicine Medical (MD/PhD) Scientist Training program. Prior to joining NYU, he was the Chief of the CNS/Pediatric Radiation Oncology Section at the University of Texas MD Anderson Cancer Center. Dr. Sulman directs a research program studying the biology of malignant brain tumors, including glioma stem cell biology, tumor microenvironment, and the mechanisms of treatment resistance. In addition, his laboratory focuses on the development of novel molecular biomarkers of treatment response and and patient outcome. He has received funding from the NCI/NIH, the NBTS, ASTRO, The Ivy Foundation, the Rose Foundation, and the ABTA, among others. In addition, he serves as the translational/correlative co-chair on some of the largest clinical trials for patients with brain tumors in both NRG Oncology and the Alliance for Clinical Trials in Oncology. He currently serves on SNO executive board of directors as Secretary/Treasurer after completing his term as Radiation Oncology Representative. In addition, he has served as the Technology Committee Chair for more than 12 years. Dr. Sulman is also the Specialty Chief Co-Editor for the Neuro-Oncology and Neurosurgical Oncology section of Frontiers in Oncology.